• SeekInClarity®

    Pan-cancer treatment response monitoring

    SeekInClarity® is the first-in-class blood-based pan-cancer pan-indication treatment response monitoring test, which uses a cutting edge multivariable molecular tumor burden (MTB) algorithm. Molecular response index (MRI) model maps the panoramic cancer genome by shallow whole genome squencing (sWGS) data, evaluates the copy number aberration (CNA),fragment size (FS) and 7 plasma protein markers, to predict tumor burden and therapeutic efficacy of the late-stage cancer patients during treatment including chemotherapy, target therapy and immunotherapy or combination therapies.

    Specifications

    Indicated subjects: Late-stage cancer patients
    Sample requirement: 10ml peripheral blood

    TAT:10 working days

    Result readout: MTB (molecular tumor burden)
    Sampling time:

  •  

    Test Workflow

     

    1

    Pre-test inquiry

    2

    Informed consent

    3

    Blood-draw

    4

    Testing

    5

    Analyzing + Interpretation

    6

    Reporting

    7

    Post-test consultation

    所有文章
    ×

    ©2018 SeekIn Cancer. All Rights Reserved.